

Date: February 12, 2026

To,
The Manager, Listing Department,
BSE Limited
Address: Phiroze Jeejeebhoy Towers,
Dalal Street, Fort, Mumbai – 400001.

Scrip Code: 540654

Subject: Outcome of Board Meeting of the Company held today i.e., February 12, 2026.

Reference: Disclosure pursuant to Regulation 30 and Regulation 33 of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 ['Listing Regulations'].

Dear Sir/Madam

This is to inform you that pursuant to Regulation 30 and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; the Board of Directors, at its meeting held today i.e. on February 12, 2026, through video conferencing deemed to be held at 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Thane, Navi Mumbai, Maharashtra, India, 400110, considered and approved the following:

- a. The Un-Audited Financial Results for the quarter ended December 31, 2025, prepared on a Standalone & Consolidated basis, along with Limited Review Report pursuant to Regulation 33 of the Securities Exchange and Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.\

Further, please be informed that the necessary disclosure under Clause 11 of Para-B of Part-A of Schedule III and Regulation 30 of the SEBI LODR Regulations read with SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026, with regard to Corporate guarantee given by the Company on behalf of Innopharm Healthcare Private Limited, subsidiary of the Company are annexed with this outcome as **Annexure A**.

Further, please note that the trading window for dealing in the Company's shares has been closed effective January 01, 2026, and shall continue to remain closed until 48 hours after the announcement of the un-audited financial results for the quarter ended December 31, 2025.

The Board Meeting commenced at 03:48 P.M. and concluded at 08:00 P.M.

Kindly note that the UDIN could not be generated due to a technical error, as the UDIN portal server was non-operational. The financials along with UDIN details will be uploaded once again when the UDIN is generated.

Kindly take the above on record.

FOR GLOBALSPACE TECHNOLOGIES LIMITED

Krishna Murari Singh
Managing Director
DIN: 03160366
Place: Mumbai

GLOBALSPACE TECHNOLOGIES LIMITED

CIN: L64201MH2010PLC211219

Formerly known as "Globalspace Technologies Private Limited"

Formerly known as "Globalspace Technologies Private Limited"

Regd. Off: Office No. 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Mahape, Navi Mumbai 400710

Tel.: 022-49452000 | **Email:** info@globalspace.in | **Website:** www.globalspace.in

Annexure A

Disclosure pursuant to Regulation 30 Read with Schedule III of the Listing Regulations and SEBI Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026:

Sr. No.	Description	Disclosure
a)	Name of party for which such guarantees or indemnity or surety was given;	M/s Innopharm Healthcare Private Limited (Subsidiary Company)
b)	whether the promoter/ promoter group/ group companies have any interest in this transaction? If yes, nature of interest and details thereof and whether the same is done at "arm's length";	No, the promoters of the Company do not have any interest in this transaction.
c)	brief details of such guarantee or indemnity or becoming a surety viz. brief details of agreement entered (if any) including significant terms and conditions, including amount of guarantee;	In consideration of Axis Bank Ltd. agreeing to lend and advance Overdraft facility aggregating to Rs.98 Lakhs to M/s Innopharm Healthcare Private Limited, which shall be availed by M/s Innopharm Healthcare Private Limited in one or more tranches, the Company has issued Corporate Guarantee dated 12.02.2026 in favour of Axis Bank inter-alia to ensure that M/s Innopharm Healthcare Private Limited abides by and complies with all the terms and conditions applicable to financial assistance including timely payment of interest & instalments, and the Company shall maintain controlling interest in M/s Innopharm Healthcare Private Limited during the tenor of the said financial assistance.
d)	impact of such guarantees or indemnity or surety on listed entity.	In the event of default by M/s Innopharm Healthcare Private Limited, the Company shall be liable to indemnify the Axis Bank and make payment of the outstanding dues under the transaction.

GLOBALSPACE TECHNOLOGIES LIMITED

CIN: L64201MH2010PLC211219

Formerly known as "Globalspace Technologies Private Limited"

Formerly known as "Globalspace Technologies Private Limited"

Regd. Off: Office No. 605, 6th Floor, Rupa Solitaire Building, Millennium Business Park, Mahape, Navi Mumbai 400710

Tel.: 022-49452000 | **Email:** info@globalspace.in | **Website:** www.globalspace.in

BANSILAL SHAH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on Standalone Quarter and Period ended December 31, 2025 Financial Results and year to date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To,
The Board of Directors,
Globalspace Technologies Limited

1. We have reviewed the unaudited financial results of GlobalSpace Technologies Limited (the 'Company') for the quarter ended and period ended December 31, 2025 (the 'Statement') attached herewith being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 which has been initialed by us for identification purposes.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind As 34) prescribed under section 133 of the Companies Act 2013 and Rule 3 of Companies (Indian Accounting Standards) Rules 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33

Of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement, except for the following:

- The inventory register maintained is not updated with details for quantity inwards and quantity outwards, movement of the inventory.
- The company has not paid all statutory payment on time. During the quarter in some delayed has been observed in case of payment of statutory payments.

For Bansilal Shah & Co.
Chartered Accountants
FRN No: 000384W



Dhruv Shah
Partner
Membership Number 223609
Place: Mumbai
Date: 12th February 2026

UDIN Could Not generated due to UDIN portal server being non-operational.

1027, Hubtown Solaris, N.S. Phadke Marg, Near Teli Gali Signal, Andheri-East, Mumbai-400069,
Phone No. 022-67410769, Email: mumbai.blsc@gmail.com, sahil.kothari1@gmail.com



GlobalSpace Technologies Limited

Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710

CIN: L64201MH2010PLC211219

Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in

Extract of Un-Audited Standalone Financial Results for the Quarter ended and nine month ended December 31, 2025

Rs in lacs

Sr. No.	Particulars	Standalone					
		Quarter Ended			Nine Months ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	INCOME						
a.	Revenue from operation	1,256.85	518.33	907.51	2,251.05	2,414.86	2,932.48
b.	Other Income	0.00		-		0.48	0.54
	Total Income	1,256.85	518.33	907.51	2,251.05	2,415.34	2,933.02
2	Expenses						
	Cost of materials Consumed	729.56	267.60	619.72	1,224.05	1,823.76	1,842.49
	Changes in Inventory of Stock in trade	251.14		26.45	345.69	26.75	52.75
	Employee Benefits Expenses	53.84	56.82	15.67	127.68	57.03	65.99
	Depreciation and Amortisation Expenses	38.72	40.88	49.13	122.87	157.44	202.74
	Finance Cost	19.21	23.47	32.01	67.02	88.04	108.83
	Other Expenses	73.82	86.02	102.63	219.06	221.05	606.05
	Total Expenses	1,166.30	474.79	845.60	2,106.38	2,374.06	2,878.85
3	Profit/Loss Before Exceptional Items and tax(1-2)	90.55	43.53	61.90	144.67	41.28	54.17
	Exceptional Items	-				-275.65	275.65
4	Profit/(Loss) before tax	90.55	43.53	61.90	144.67	-234.37	-221.48
	Tax Expense						
	Current Tax	10.73	13.95		30.71		
	Deferred Tax	33.54	11.75		37.77	-41.94	-37.75
	Total Tax Expenses	44.27	25.70	-	68.48	-41.94	-37.75
6	Net Profit/(Loss) after tax(4-5)	46.27	17.84	61.90	76.18	-192.44	-183.73
7	Other Comprehensive Income						
	Items that will not be reclassified into Profit or Loss						
		-		0.50		-	-6.41
	Total Comprehensive Income	-	-	-	-	-	-6.41
8	Total Comprehensive Income for the year (after tax) (6+7)	46.27	17.84	62.40	76.18	-192.44	-190.14
11	Paid-up Equity Share Capital (Face Value of Re. 10 /- each)	3,436.98	3,436.98	3,436.98	3,436.98	3,436.98	1,145.66
12	Other Equity	2,089.92	2,043.65	2,011.42	2,089.92	2,011.42	2,013.74
13	Earnings per Equity Share (of Rs. 10/- each)						
	Basic	1.64	0.05	0.59	0.61	-1.82	-1.66
	Diluted	1.64	0.05	0.59	0.61	-1.82	-1.66

Not

- The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 12th February 2026
- The Statutory auditors have conducted the Quarterly and nine month ended Review of the financial statements and have expressed an unqualified audit opinion.
- Previous period figures have been re-grouped / re-classified wherever necessary.

For Bansilal Shah & Co
Chartered Accountants
FRN No : 000384W

Dhruv Shah

CA Dhruv Shah
Partner

Membership No : 223609

UDIN: UDIN COULD NOT BE GENERATED DUE TO UDIN

PORTAK BEING NON OPERATIONAL

Place: Mumbai

Date : 12.02.2026



For Globalspace Technologies Limited

Krishna Murari Singh

Krishna Murari Singh
Chairman and Managing Director
DIN : 03160366



Place: Navi Mumbai

Date : 12.02.2026

BANSILAL SHAH & CO.

CHARTERED ACCOUNTANTS

Independent Auditor's Limited Review Report on Consolidated Unaudited Quarter and Period ended December 31, 2025 Financial Results and year to date results of the company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.

To,
The Board of Directors,
Globalspace Technologies Limited

1. We have reviewed the unaudited financial results of GlobalSpace Technologies Limited (the 'Company') for the quarter and Period ended December 31, 2025 (the 'Statement') attached herewith being submitted by the Company pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 which has been initialed by us for identification purposes.

2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting (Ind As 34) prescribed under section 133 of the Companies Act 2013 and Rule 3 of Companies (Indian Accounting Standards) Rules 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. The Statement includes the results of the following entities:

Sr. No.	Name of the Entity	Relationship
1.	Global Technologies Limited	Holding Company
2.	Miljon Medi App Private Limited	Subsidiary Company with 95.00% holding
3.	Innopharma Healthcare Private Limited	Subsidiary Company with 51.00% holding

5. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying Statement prepared in accordance with the aforesaid Accounting Standards and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 Of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2025 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement, except for the following:

- The accounts of the subsidiary have been not been reviewed by us and we have relied upon the financial statement as drafted by the Management of the subsidiary.

For Bansilal Shah & Co.
Chartered Accountants
FRN No: 000384W



Dhruv Shah
Partner
Membership Number 223609
Place: Mumbai
Date: 12th February 2026

UDIN Could Not generated due to UDIN portal server being non-operational.



GlobalSpace Technologies Limited
Address: 605, Rupa Solitaire Building, Millenium Business Park, Navi Mumbai, Thane - 400710
CIN: L64201MH2010PLC211219

Tel No : 022-49452015, Email id:- cs@globalspace.in, website:- www.globalspace.in

Extract of Un-Audited Standalone and Consolidated Financial Results for the quarter ended December 31, 2025

Rs in lacs

Sr. No.	Particulars	Consolidated					
		Quarter Ended			Nine Months ended		Year Ended
		31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	INCOME						
a.	Revenue from operation	1,663.50	1,001.07	1,268.98	3,542.43	3,429.45	4,304.58
b.	Other Income	0.75	0.76	1.76	2.30	3.82	4.59
	Total Income	1,664.25	1,001.83	1,270.74	3,544.73	3,433.27	4,309.17
2	Expenses						
	Cost of materials Consumed	722.83	267.60	619.72	1,217.32	1,823.76	1,830.67
	Changes in Inventory of Stock in trade	251.14		26.45	345.69	26.75	52.75
	Employee Benefits Expenses	309.11	365.42	291.71	946.67	842.40	937.18
	Depreciation and Amortisation Expenses	45.17	53.30	49.56	141.92	158.64	234.72
	Finance Cost	19.21	23.47	32.01	67.02	88.04	108.86
	Other Expenses	222.61	252.85	183.49	678.27	443.13	1,111.83
	Total Expenses	1,570.08	962.64	1,202.93	3,396.90	3,382.71	4,276.00
3	Profit/Loss Before Exceptional Items and tax(1-2)	94.17	39.19	67.81	147.83	50.56	33.17
	Exceptional Items			-	-	-275.65	275.65
	Finance Cost						
4	Profit/(Loss)before tax	94.17	39.19	67.81	147.83	-225.09	-242.48
	Tax Expense						
	Current Tax	13.09	16.96	0.41	36.09	1.22	2.59
	Deferred Tax	44.87	34.22	0.02	71.57	-41.88	-45.15
	Total Tax Expenses	57.95	51.18	0.42	107.65	-40.65	-42.56
6	Net Profit/(Loss) after tax(4-5)	36.22	-11.98	67.38	40.18	-184.43	-199.92
7	Other Comprehensive Income						
	Items that will not be reclassified into Profit or Loss	-					-6.41
	Total Comprehensive Income						-6.41
	Less: Share of minority	3.57	4.29		7.86		8.15
8	Total Comprehensive Income for the year (after tax) (5+6)	36.22	-16.27	67.38	40.18	-184.43	-214.48
10	Less: Share of Non Controlling Interest						
11	Total Comprehensive Income for the year (after tax) for controlling interest (5+6)	36.22	-16.27	67.38	40.18	(184.43)	(214.48)
12	Paid-up Equity Share Capital (Face Value of Re. 10 /- each)	3,436.98	3,436.98	3,436.98	3,436.98	3,436.98	3,436.98
13	Other Equity	2,023.31	1,987.09	2,019.72	2,029.56	2,019.43	1,989.38
14	Earnings per Equity Share (of Rs. 10/- each)						
	Basic	0.11	-0.05	0.20	0.12	(0.54)	(1.75)
	Diluted	0.11	-0.05	0.20	0.12	(0.54)	(1.75)

1

The above results were reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 12th February 2026

2

The Statutory auditors have conducted the Review of the financial statements and have expressed an un qualified audit opinion.

3

Previous period figures have been re-grouped / re-classified wherever necessary.

For Bansilal Shah & Co
Chartered Accountants
FRN No : 000384W

[Signature]

CA Dhruv Shah
Partner

Membership No : 223609

UDIN: UDIN COULD NOT BE GENERATED DUE TO UDIN

PORTAK BEING NON OPERATIONAL

Place: Mumbai

Date : 12.02.2026



For Globalspace Technologies Limited

[Signature]

Krishna Murari Singh

Chairman and Managing Director

DIN : 03160366

Place: Navi Mumbai

Date : 12.02.2026

